Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate cancer ...
Read moreStudy highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate cancer ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.